Skip to main content
SpringerLink
Log in

PET studies in dementia

  • Review
  • Published:
Annals of Nuclear Medicine Aims and scope Submit manuscript

Abstract

Measurement of local cerebral glucose metabolism (lCMRGlc) by positron emission tomography (PET) and18F-2-fluoro-2-deoxy-d-glucose (FDG) has become a standard technique during the past 20 years and is now available at many university hospitals in all highly developed countries. Many studies have documented a close relation between lCMRGlc and localized cognitive functions, such as language and visuoconstructive abilities. Alzheimer’s disease (AD) is characterized by regional impairment of cerebral glucose metabolism in neocortical association areas (posterior cingulate, temporoparietal and frontal multimodal association cortex), whereas primary visual and sensorimotor cortex, basal ganglia, and cerebellum are relatively well preserved. In a multicenter study comprising 10 PET centers (Network for Efficiency and Standardisation of Dementia Diagnosis, NEST-DD) that employed an automated voxel-based analysis of FDG PET images, the distinction between controls and AD patients was 93% sensitive and 93% specific, and even in very mild dementia (at MMSE 24 or higher) sensitivity was still 84% at 93% specificity. Significantly abnormal metabolism in mild cognitive deficit (MCI), indicates a high risk to develop dementia within the next two years. Reduced neocortical glucose metabolism can probably be detected with FDG PET in AD on average one year before onset of subjective cognitive, impairment. In addition to glucose metabolism, specific tracers for dopamine synthesis (18F-F-DOPA), and for (11C-MP4A) are of interest for differentiation among dementia subtypes. Cortical acetylcholine esterase activity (AChE) activity is significantly lower in patients with AD or with dementia with Lewy bodies (DLB) than in age-matched normal controls. In LBD there is also impairment of dopamine synthesis, similar to Parkinson disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Petersen RC, Stevens JC, Ganguli M, Tangalos EG, Cummings JL, Dekosky ST. Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology.Neurology 2001; 56 (9): 1133–1142.

    PubMed  CAS  Google Scholar 

  2. Frackowiak RS, Magistretti PJ, Shulman RG, Altman JS, Adams M. Neuroenergetics: Relevance for functional brain imaging. Strasbourg: Human Frontier Science Program; 2001.

    Google Scholar 

  3. Sokoloff L. Localization of functional activity in the central nervous system by measurement of glucose utilization with radioactive deoxyglucose. [Review]J Cereb Blood Flow Metab 1981; 1 (1): 7–36.

    PubMed  CAS  Google Scholar 

  4. Mata M, Fink DJ, Gainer H, Smith CB, Davidsen L, Savaki H, et al. Activity-dependent energy metabolism in rat posterior pituitary primarily reflects sodium pump activityJ Neurochem 1980; 34 (1): 213–215.

    Article  PubMed  CAS  Google Scholar 

  5. Sibson NR, Dhankhar A, Mason GF, Rothman DL, Behar KL, Shulman RG. Stoichiometric coupling of brain glucose metabolism and glutamatergic neuronal activity.Proc Natl Acad Sci USA 1998; 95 (1): 316–321.

    Article  PubMed  CAS  Google Scholar 

  6. Foster NL, Chase TN, Fedio P, Patronas NJ, Brooks RA, Di Chiro G. Alzheimer’s disease: focal cortical changes shown by positron emission tomography.Neurology 1983; 33 (8): 961–965.

    PubMed  CAS  Google Scholar 

  7. Herholz K. FDG PET and differential diagnosis of dementia.Alzheimer Disease & Associated Disorders 1995; 9 (1): 6–16.

    Article  CAS  Google Scholar 

  8. Herholz K, Salmon E, Perani D, Baron JC, Holthoff V, Frölich L, et al. Discrimination between Alzheimer Dementia and Controls by Automated Analysis of Multicenter FDG PET.Neuroimage 2002; 17: 302–316.

    Article  PubMed  CAS  Google Scholar 

  9. Zuendorf G, Kerrouche N, Herholz K, Baron JC. An efficient principal component analysis for multivariate 3D voxelbased mapping of brain functional imaging data sets as applied to FDG-PET and normal aging.Hum Brain Mapp 2003; 18: 13–21.

    Article  PubMed  Google Scholar 

  10. Minoshima S, Giordani B, Berent S, Frey KA, Foster NL, Kuhl DE. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer’s disease.Ann Neurol 1997; 42 (1): 85–94.

    Article  PubMed  CAS  Google Scholar 

  11. Gusnard DA, Raichle ME, Raichle ME. Searching for a baseline: functional imaging and the resting human brain.Nat Rev Neurosci 2001; 2 (10): 685–694.

    Article  PubMed  CAS  Google Scholar 

  12. Burdette JH, Minoshima S, Vander Borght T, Tran, DD, Kuhl DE. Alzheimer disease: improved visual interpretation of PET images by using three-dimensional stereotaxic surface projections.Radiology 1996; 198 (3): 837–843.

    PubMed  CAS  Google Scholar 

  13. Signorini M, Paulesu E, Friston K, Perani D, Colleluori A, Lucignani G, et al. Rapid assessment of regional cerebral metabolic abnormalities in single subjects with quantitative and nonquantitative [18F]FDG PET: A clinical validation of statistical parametric mapping.Neuroimage 1999; 9 (1): 63–80.

    Article  PubMed  CAS  Google Scholar 

  14. Ishii K, Willock F, Minoshima S, Drzezga A, Ficaro EP, Cross DJ, et al. Statistical brain mapping of18F-FDG PET in Alzheimer’s disease: validation of anatomic standardization for atrophied brains.J Nucl Med 2001; 42 (4): 548–557.

    PubMed  CAS  Google Scholar 

  15. Salmon E, Collette F, Degueldre C, Lemaire C, Franck G. Voxel-based analysis of confounding effects of age and dementia severity on cerebral metabolism in Alzheimer’s disease.Hum Brain Mapp 2000; 10 (1): 39–48.

    Article  PubMed  CAS  Google Scholar 

  16. Braak H, Braak E. Frequency of stages of Alzheimer-related lesions in different age categories.Neurobiol Aging 1997; 18 (4): 351–357.

    Article  PubMed  CAS  Google Scholar 

  17. Petersen RC, Doody R, Kurz A, Mohs RC, Morris JC, Rabins PV, et al. Current concepts in mild cognitive impairment.Arch Neurol 2001; 58 (12): 1985–1992.

    Article  PubMed  CAS  Google Scholar 

  18. McKhann G, Drachman D, Folstein MF, Katzman R, Price, D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease.Neurology 1984; 34: 939–944.

    PubMed  CAS  Google Scholar 

  19. Herholz K, Nordberg A, Salmon E, Perani D, Kessler J, Mielke R, et al. Metabolic impairment of association cortex predicts progression in Alzheimer’s disease: a prospective multicenter positron emission tomography (PET) study.Eur J Neurol 1998; 5 (Suppl 3): S24.

    Google Scholar 

  20. Arnaiz E, Jelic V, Almkvist O, Wahlund LO, Winblad B, Valind S, et al. Impaired cerebral glucose metabolism and cognitive functioning predict deterioration in mild cognitive impairment.Neuroreport 2001; 12 (4): 851–855.

    Article  PubMed  CAS  Google Scholar 

  21. Drzezga A, Lautenschlager N, Minoshima S, Spiegel S, Kurz A, Schwaiger M. Early identification of patients with Alzheimer’s disease in a MCI group using F-18 FDG PET.J Cereb Blood Flow Metab 2001; 21 (Suppl): S426.

    Google Scholar 

  22. Reiman EM, Caselli RJ, Chen K, Alexander GE, Bandy D, Frost J. Declining brain activity in cognitively normal apolipoprotein E epsilon 4 heterozygotes: A foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer’s disease.Proc Natl Acad Sci USA 2001; 98 (6): 3334–3339.

    Article  PubMed  CAS  Google Scholar 

  23. Reiman EM, Caselli RJ, Yun LS, Chen K, Bandy D, Minoshima S, et al. Preclinical evidence of Alzheimer’s disease in persons homozygous for the epsilon 4 allele for apolipoprotein E.N Engl J Med 1996; 334 (12): 752–758.

    Article  PubMed  CAS  Google Scholar 

  24. de Leon MJ, Convit A, Wolf OT, Tarshish CY, DeSanti S, Rusinek H, et al. Prediction of cognitive decline in normal elderly subjects with 2-F-18-fluoro-2-deoxy-d-glucose positron-emission tomography (FDGPET).Proc Natl Acad Sci USA 2001; 98 (19): 10966–10971.

    Article  PubMed  Google Scholar 

  25. Yamaguchi S, Meguro K, Itoh M, Hayasaka C, Shimada M, Yamazaki H, et al. Decreased cortical glucose metabolism correlates with hippocampal atrophy in Alzheimer’s disease as shown by MRI and PET.J Neurol Neurosurg Psychiatry 1997; 62 (6): 596–600.

    Article  PubMed  CAS  Google Scholar 

  26. Wilson RS, Barnes LL, Mendes de Leon CF, Aggarwal NT, Schneider JS, Bach J, et al. Depressive symptoms, cognitive decline, and risk of AD in older persons.Neurology 2002; 59 (3): 364–370.

    PubMed  Google Scholar 

  27. Mayberg HS, Liotti M, Brannan SK, McGinnis S, Mahurin RK, Jerabek PA, et al. Reciprocal limbic-cortical function and negative mood: converging PET findings in depression and normal sadness.Am J Psychiatry 1999; 156 (5): 675–682.

    PubMed  CAS  Google Scholar 

  28. Hirono N, Mori E, Ishii K, Ikejiri Y, Imamura T, Shimomura T, et al. Frontal lobe hypometabolism and depression in Alzheimer’s disease.Neurology 1998; 50 (2): 380–383.

    PubMed  CAS  Google Scholar 

  29. Herholz K, Nordberg A, Salmon E, Perani D, Kessler J, Mielke R, et al. Impairment of neocortical metabolism predicts progression in Alzheimer’s disease.Dement Geriatr Cogn Disord 1999; 10 (6): 494–504.

    Article  PubMed  CAS  Google Scholar 

  30. Kumar A, Newberg A, Alavi A, Berlin J, Smith R, Reivich M. Regional cerebral glucose metabolism in late-life depression and Alzheimer disease: a preliminary positron emission tomography study.Proc Natl Acad Sci USA 1993; 90 (15): 7019–7023.

    Article  PubMed  CAS  Google Scholar 

  31. Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, Black S, et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria.Neurology 1998; 51 (6): 1546–1554.

    PubMed  CAS  Google Scholar 

  32. Kertesz A, Munoz D. Pick’s disease, frontotemporal dementia, and Pick complex: emerging concepts.Arch Neurol 1998; 55 (3): 302–304.

    Article  PubMed  CAS  Google Scholar 

  33. Lindau M, Almkvist O, Kushi J, Boone K, Johansson SE, Wahlund LO, et al. First symptoms—frontotemporal dementia versus Alzheimer’s disease.Dement Geriatr Cogn Disord 2000; 11 (5): 286–293.

    Article  PubMed  CAS  Google Scholar 

  34. van Swieten JC, Stevens M, Rosso SM, Rizzu P, Joosse M, de Koning I, et al. Phenotypic variation in hereditary frontotemporal dementia with tau mutations.Ann Neurol 1999; 46 (4): 617–626.

    Article  PubMed  Google Scholar 

  35. Hosaka K, Ishii K, Sakamoto S, Mori T, Sasaki M, Hirono N, et al. Voxel-based comparison of regional cerebral glucose metabolism between PSP and corticobasal degeneration.J Neurol Sci 2002; 199 (1–2): 67–71.

    Article  PubMed  CAS  Google Scholar 

  36. Feany MB, Mattiace LA, Dickson DW. Neuropathologic overlap of progressive supranuclear palsy, Pick’s disease and corticobasal degeneration.J Neuropathol Exp Neurol 1996; 55 (1): 53–67

    Article  PubMed  CAS  Google Scholar 

  37. Karbe H, Grond M, Huber M, Herholz K, Kessler J, Heiss WD. Subcortical damage and cortical dysfunction in progressive supranuclear palsy demonstrated by positron emission tomography.J Neurol 1992; 239 (2): 98–102.

    Article  PubMed  CAS  Google Scholar 

  38. Soong B, Liu R, Wu L, Lu Y, Lee H. Metabolic characterization of spinocerebellar ataxia type 6.Arch Neurol 2001; 58 (2): 300–304.

    Article  PubMed  CAS  Google Scholar 

  39. Volkow ND, Hitzemann R, Wang GJ, Fowler JS, Wolf AP, Dewey SL, et al. Long-term frontal brain metabolic changes in cocaine abusers.Synapse 1992; 11 (3): 184–190.

    Article  PubMed  CAS  Google Scholar 

  40. Erkinjuntti T, Ostbye T, Steenhuis R, Hachinski V. The effect of different diagnostic criteria on the prevalence of dementia.N Engl J Med 1997; 337 (23): 1667–1674.

    Article  PubMed  CAS  Google Scholar 

  41. Chui HC, Mack W, Jackson JE, Mungas D, Reed BR, Tinklenberg J, et al. Clinical criteria for the diagnosis of vascular dementia: a multicenter study of comparability and interrater reliability.Arch Neurol 2000; 57 (2): 191–196.

    Article  PubMed  CAS  Google Scholar 

  42. Jellinger KA. The pathology of ischemic-vascular dementia: An update.J Neurol Sci 2002; 203-204: 153–157.

    Article  PubMed  Google Scholar 

  43. Ikeda M, Hokoishi K, Maki N, Nebu A, Tachibana N, Komori K, et al. Increased prevalence of vascular dementia in Japan: a community-based epidemiological study.Neurology 2001; 57 (5): 839–844.

    PubMed  CAS  Google Scholar 

  44. Mielke R, Herholz K, Grond M, Kessler J, Heiss WD. Severity of vascular dementia is related to volume of metabolically impaired tissue.Arch Neurol 1992; 49 (9): 909–913.

    PubMed  CAS  Google Scholar 

  45. Sultzer DL, Mahler ME, Cummings JL, Van Gorp WG, Hinkin CH, Brown C. Cortical abnormalities associated with subcortical lesions in vascular dementia. Clinical and position emission tomographic findings.Arch Neurol 1995; 52 (8): 773–780.

    PubMed  CAS  Google Scholar 

  46. Johnson KA, Mueller ST, Walshe TM, English RJ, Holman BL. Cerebral perfusion imaging in Alzheimer’s disease. Use of single photon emission computed tomography and iofetamine hydrochloride I-123.Arch Neurol 1987; 44 (2): 165–168.

    PubMed  CAS  Google Scholar 

  47. Powers WJ, Perlmutter JS, Videen TO, Herscovitch P, Griffeth LK, Royal HD, et al. Blinded clinical evaluation of positron emission tomography for diagnosis of probable Alzheimer’s disease.Neurology 1992; 42 (4): 765–770.

    PubMed  CAS  Google Scholar 

  48. Frackowiak RS, Pozzilli C, Legg NJ, Du Boulay GH, Marshall J, Lenzi GL, et al. Regional cerebral oxygen supply and utilization in dementia. A clinical and physiological study with oxygen-15 and positron tomography.Brain 1981; 104 (Pt 4): 753–778.

    Article  PubMed  CAS  Google Scholar 

  49. Fukuyama H, Ogawa M, Yamauchi H, Yamaguchi S, Kimura J, Yonekura Y, et al. Altered cerebral energy metabolism in Alzheimer’s disease: a PET study.J Nucl Med 1994; 35 (1): 1–6.

    PubMed  CAS  Google Scholar 

  50. Nagata K, Maruya H, Yuya H, Terashi H, Mito Y, Kato H, et al. Can PET data differentiate Alzheimer’s disease from vascular dementia?Ann NY Acad Sci 2000; 903: 252–261.

    Article  PubMed  CAS  Google Scholar 

  51. Silverman DH, Small GW, Chang CY, Lu CS, Kung de Aburto MA, Chen W, et al. Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome.JAMA 2001; 286 (17): 2120–2127.

    Article  PubMed  CAS  Google Scholar 

  52. Herholz K, Schopphoff H, Schmidt M, Mielke R, Eschner W, Scheidhauer K, et al. Direct comparison of spatially normalized PET and SPECT scans in Alzheimer disease.J Nucl Med 2002; 43 (1): 21–26.

    PubMed  Google Scholar 

  53. Mielke R, Pietrzyk U, Jacobs A, Fink GR, Ichimiya A, Kessler J, et al. HMPAO SPET and FDG PET in Alzheimer’s disease and vascular dementia: comparison of perfusion and metabolic pattern.Eur J Nucl Med 1994; 21 (10): 1052–1060.

    Article  PubMed  CAS  Google Scholar 

  54. Messa C, Perani D, Lucignani G, Zenorini A, Zito F, Rizzo G, et al. High-resolution technetium-99m-HMPAO SPECT in patients with probable Alzheimer’s disease: comparison with fluorine-18-FDG PET.J Nucl Med 1994; 35 (2): 210–216.

    PubMed  CAS  Google Scholar 

  55. Silverman DHS, Cummings JL, Small GW, Gambhir SS, Chen W, Czernin J, et al. Added Clinical Benefit of Incorporating 2-Deoxy-2-[18F]Fluoro-d-Glucose with Positron Emission Tomography into the Clinical Evaluation of Patients with Cognitive Impairment.Molecular Imaging & Biology 2002; 4 (4): 283–293.

    Article  Google Scholar 

  56. Okamura N, Arai H, Maruyama M, Higuchi M, Matsui T, Tanji H, et al. Combined Analysis of CSF Tau Levels and [(123)I]Iodoamphetamine SPECT in Mild Cognitive Impairment: Implications for a Novel Predictor of Alzheimer’s Disease.Am J Psychiatry 2002; 159 (3): 474–476.

    Article  PubMed  Google Scholar 

  57. Huang C, Wahlund LO, Svensson L, Winblad B, Julin P. Cingulate cortex hypoperfusion predicts Alzheimer’s disease in mild cognitive impairment.BMC Neurol 2002; 2 (1): 9.

    Article  PubMed  Google Scholar 

  58. Minoshima S, Foster NL, Sima AA, Frey KA, Albin RL, Kuhl DE. Alzheimer’s disease versus dementia with Lewy bodies: cerebral metabolic distinction with autopsy confirmation.Ann Neurol 2001; 50 (3): 358–365.

    Article  PubMed  CAS  Google Scholar 

  59. Ishii K, Imamura T, Sasaki M, Yamaji S, Sakamoto S, Kitagaki H, et al. Regional cerebral glucose metabolism in dementia with Lewy bodies and Alzheimer’s disease.Neurology 1998; 51 (1): 125–130.

    PubMed  CAS  Google Scholar 

  60. Eidelberg D, Moeller JR, Dhawan V, Spetsieris P, Takikawa S, Ishikawa T, et al. The metabolic topography of parkinsonism.J Cereb Blood Flow Metab 1994; 14 (5): 783–801.

    PubMed  CAS  Google Scholar 

  61. Brooks DJ. PET studies on the early and differential diagnosis of Parkinson’s disease.Neurology 1993; 43 (12 Suppl 6): S6–16.

    Google Scholar 

  62. Perry RH, Irving D, Blessed G, Fairbairn A, Perry EK. Senile dementia of Lewy body type. A clinically and neuropathologically distinct form of Lewy body dementia in the elderly.J Neurol Sci 1990; 95 (2): 119–139.

    Article  PubMed  CAS  Google Scholar 

  63. Verghese J, Crystal HA, Dickson DW, Lipton RB. Validity of clinical criteria for the diagnosis of dementia with Lewy bodies.Neurology 1999; 53 (9): 1974–1982.

    PubMed  CAS  Google Scholar 

  64. Jellinger KA. Morphological substrates of mental dysfunction in Lewy body disease: an update.J Neural Transm Suppl 2000; 59 (1–2): 185–212.

    PubMed  CAS  Google Scholar 

  65. Holthoff-Detto VA, Kessler J, Herholz K, Bönner H, Pietrzyk U, Würker M, et al. Functional effects of striatal dysfunction in Parkinson disease.Arch Neurol 1997; 54: 145–150.

    PubMed  CAS  Google Scholar 

  66. Ito K, Nagano-Saito A, Kato T, Arahata Y, Nakamura A, Kawasumi Y, et al. Striatal and extrastriatal dysfunction in Parkinson’s disease with dementia: a 6-[(18)F]fluolo-l-dopa PET study.Brain 2002; 125 (Pt 6): 1358–1365.

    Article  PubMed  Google Scholar 

  67. Hu XS, Okamura N, Arai H, Higuchi M, Matsui T, Tashiro M, et al.18F-fluorodopa PET study of striatal dopamine uptake in the diagnosis of dementia with lewy bodies.Neurology 2000; 55 (10): 1575–1577.

    PubMed  CAS  Google Scholar 

  68. Rinne JO, Ruottinen H, Bergman J, Haaparanta M, Sonninen P, Solin O. Usefulness of a dopamine transporter PET ligand[(18)F]beta-CFT in assessing disability in Parkinson’s disease.J Neurol Neurosurg Psychiatry 1999; 67 (6): 737–741.

    Article  PubMed  CAS  Google Scholar 

  69. Vander Borght TM, Kilbourn MR, Koeppe RA, DaSilva JN, Carey JE, Kuhl DE, et al.In vivo imaging of the brain vesicular monoamine transporter.J Nucl Med 1995; 36 (12): 2252–2260.

    Google Scholar 

  70. Bartus RT, Dean RL, Beer B, Lippa AS. The cholinergic hypothesis of geriatric memory dysfunction.Science 1982; 217 (4558): 408–414.

    Article  PubMed  CAS  Google Scholar 

  71. Peny EK, Haroutunian V, Davis KL, Levy R, Lantos P, Eagger S, et al. Neocortical cholinergic activities differentiate Lewy body dementia from classical Alzheimer’s disease.Neuroreport 1994; 5 (7): 747–749.

    Article  Google Scholar 

  72. Candy JM, Perry RH, Perry EK, Irving D, Blessed G, Fairbairn AF, et al. Pathological changes in the nucleus basalis of Meynert in Alzheimer’s and Parkinson’s disease.J Neurol Sci 1983; 59: 277–289.

    Article  PubMed  CAS  Google Scholar 

  73. Mann DM, Yates PO, Marcyniuk B. The nucleus basalis of Meynert in multi-infarct (vascular) dementia.Acta Neuropathol (Berl) 1986; 71 (3–4): 332–337.

    Article  CAS  Google Scholar 

  74. Snyder SE, Tluczek L, Jewett DM, Nguyen TB, Kuhl DE, Kilbourn MR. Synthesis of 1-[11C]methylpiperidin-4-yl propionate ([11C]PMP) forin vivo measurements of acetyl-cholinesterase activity.Nucl Med Biol 1998; 25 (8): 751–754.

    Article  PubMed  CAS  Google Scholar 

  75. Namba H, Irie T Fukushi K, Iyo M.In vivo measurement of acetylcholinesterase activity in the brain with a radioactive acetylcholine analog.Brain Research 1994; 667 (2): 278–282.

    Article  PubMed  CAS  Google Scholar 

  76. Zündorf G, Herholz K, Lercher M, Wienhard K, Bauer B, Weisenbach S, Heiss W-D. PET functional parametric images of acetylcholine esterase activity without blood sampling. Senda M, Kimura Y, Herscovitch P, eds.Brain Imaging Using PET. San Diego, Ca.; Academic Press, 2002: 41–46.

    Chapter  Google Scholar 

  77. Herholz K, Lercher M, Wienhard K, Bauer B, Lenz O, Heiss W-D. PET measurement of cerebral acetylcholine esterase activity without blood sampling.Eur J Nucl Med 2001; 28: 472–477.

    Article  PubMed  CAS  Google Scholar 

  78. Shinotoh H, Namba H, Fukushi K, Nagatsuka S, Tanaka N, Aotsuka A, et al. Progressive loss of cortical acetylcholinesterase activity in association with cognitive decline in Alzheimer’s disease: a positron emission tomography study.Ann Neurol 2000; 48 (2): 194–200.

    Article  PubMed  CAS  Google Scholar 

  79. Herholz K, Bauer B, Wienhard K, Kracht L, Mielke R, Lenz O, et al.In-vivo measurements of regional acetylcholine esterase activity in degenerative dementia: comparison with blood flow and glucose metabolism.J Neural Transm 2000; 12: 1457–1468.

    Article  Google Scholar 

  80. Perry EK, Irving D, Kerwin JM, McKeith IG, Thompson P, Collerton D, et al. Cholinergic transmitter and neurotrophic activities in Lewy body dementia: similarity to Parkinson’s and distinction from Alzheimer disease.Alzheimer Disease & Associated Disorders 1993; 7 (2): 69–79.

    Article  CAS  Google Scholar 

  81. Volkow ND, Ding YS, Fowler JS, Gatley SJ. Imaging brain cholinergic activity with positron emission tomography: its role in the evaluation of cholinergic treatments in Alzheimer’s dementia.Biol Psychiatry 2001; 49 (3): 211–220.

    Article  PubMed  CAS  Google Scholar 

  82. Sihver W, Langstrom B, Nordberg A. Ligands forin vivo imaging of nicotinic receptor subtypes in Alzheimer brain.Acta Neurol Scand Suppl 2000; 176: 27–33.

    Article  PubMed  CAS  Google Scholar 

  83. Bacskai BJ, Klunk WE, Mathis CA, Hyman BT. Imaging Amyloid-beta DepositsIn Vivo.J Cereb Blood Flow Metab 2002; 22 (9): 1035–1041.

    Article  PubMed  CAS  Google Scholar 

  84. Shoghi-Jadid K, Small GW, Agdeppa ED, Kepe V, Ercoli LM, Siddarth P, et al. Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease.Am J Geriatr Psychiatry 2002; 10 (1): 24–35.

    Article  PubMed  Google Scholar 

  85. Rapoport SI. Positron emission tomography in Alzheimer’s disease in relation to disease pathogenesis—a critical review.Cerebrovascular & Brain Metabolism Reviews 1991; 3 (4): 297–335.

    CAS  Google Scholar 

  86. Imamura T, Ishii K, Hirono N, Hashimoto M, Tanimukai S, Kazui H, et al. Occipital glucose metabolism in dementia with lewy bodies with and without parkinsonism: a study using positron emission tomography.Dement Geriatr Cogn Disord 2001; 12 (3): 194–197.

    Article  PubMed  CAS  Google Scholar 

  87. Higuchi M, Tashiro M, Arai H, Okamura N, Hara S, Higuchi S, et al. Glucose hypometabolism and neuropathological correlates in brains of dementia with Lewy bodies.Exp Neurol 2000; 162 (2): 247–256.

    Article  PubMed  CAS  Google Scholar 

  88. Salmon E, Delbeuck X, Garraux G, Collette F, Herholz K, Kalbe E, et al. A predominant ventromedial frontopolar metabolic impairment demonstrated in frontotemporal dementia.J Neurol 2002; 249 (Suppl 1): 14.

    Google Scholar 

  89. Jauss M, Herholz K, Kracht L, Pantel J, Hartmann T, Jensen M, et al. Frontotemporal dementia: Clinical, neuroimaging, and molecular biological findings in 6 patients.European Archives of Psychiatry & Clinical Neuroscience 2001; 251: 225–231.

    Article  CAS  Google Scholar 

  90. Ishii K, Sakamoto S, Sasaki M, Kitagaki H, Yamaji S, Hashimoto M, et al. Cerebral glucose metabolism in patients with frontotemporal dementia.J Nucl Med 1998; 39 (11): 1875–1878.

    PubMed  CAS  Google Scholar 

  91. Friedland RP, Koss E, Lemer A, Hedera P, Ellis W, Dronkers N, et al. Functional imaging, the frontal lobes, and dementia.Dementia 1993; 4 (3–4): 192–203.

    Article  PubMed  CAS  Google Scholar 

  92. Hilker R, Voges J, Thiel A, Ghaemi M, Herholz K, Sturm V, et al. Deep brain stimulation of the subthalamic nucleus versus levodopa challenge in Parkinson’s disease: measuring the on- and off-conditions with FDG-PET.J Neural Transmission 2002; 10: 1257–1264.

    Article  Google Scholar 

  93. Berding G, Odin P, Brooks DJ, Nikkhah G, Matthies C, Peschel T, et al. Resting regional cerebral glucose metabolism in advanced Parkinson’s disease studied in the off and on conditions with [(18)F]FDG-PET.Mov Disord 2001; 16 (6): 1014–1022.

    Article  PubMed  CAS  Google Scholar 

  94. Fukuda M, Mentis MJ, Ma Y, Dhawan V, Antonini A, Lang AE, et al. Networks mediating the clinical effects of pallidal brain stimulation for Parkinson’s disease: a PET study of resting-state glucose metabolism.Brain 2001; 124 (Pt 8): 1601–1609.

    Article  PubMed  CAS  Google Scholar 

  95. Su PC, Ma Y, Fukuda M, Mentis MJ, Tseng HM, Yen RF, et al. Metabolic changes following subthalamotomy for advanced Parkinson’s disease.Ann Neurol 2001; 50 (4): 514–520.

    Article  PubMed  CAS  Google Scholar 

  96. Bohnen NI, Minoshima S, Giordani B, Frey KA, Kuhl DE. Motor correlates of occipital glucose hypometabolism in Parkinson’s disease without dementia.Neurology 1999; 52 (3): 541–546.

    PubMed  CAS  Google Scholar 

  97. Eidelberg D, Moeller JR, Dhawan V, Sidtis JJ, Ginos JZ, Strother SC, et al. The metabolic anatomy of Parkinson’s disease: complementary [18F] fluorodeoxyglucose and [18F]fluorodopa positron emission tomographic studies.Movement Disorders 1990; 5 (3): 203–213.

    Article  PubMed  CAS  Google Scholar 

  98. Eidelberg D, Takikawa S, Moeller JR, Dhawan V, Redington K, Chaly T, et al. Striatal hypometabolism distinguishes striatonigral degeneration from Parkinson’s disease.Ann Neurol 1993; 33 (5): 518–527.

    Article  PubMed  CAS  Google Scholar 

  99. Taniwaki T, Nakagawa M, Yamada T, Yoshida T, Ohyagi Y, Sasaki M, et al. Cerebral metabolic changes in early multiple system atrophy: a PET study.J Neurol Sci 2002; 200 (1–2): 79–84.

    Article  PubMed  Google Scholar 

  100. Ghaemi M, Hilker R, Rudolf J, Sobesky J, Heiss WD. Differentiating multiple system atrophy from Parkinson’s disease: contribution of striatal and midbrain MRI volumetry and multi-tracer PET imaging.J Neurol Neurosurg Psychiatry 2002; 73 (5): 517–523.

    Article  PubMed  CAS  Google Scholar 

  101. Fulham MJ, Dubinsky RM, Pohnsky RJ, Brooks RA, Brown RT, Curras MT, et al. Computed tomography, magnetic resonance imaging and positron emission tomography with [18F]fluorodeoxyglucose in multiple system atrophy and pule autonomic failure.Clinical Autonomic Research 1991; 1 (1): 27–36.

    Article  PubMed  CAS  Google Scholar 

  102. Gilman S, Koeppe RA, Junck L, Kluin KJ, Lohman M, St Laurent RT. Patterns of cerebral glucose metabolism detected with positron emission tomography differ in multiple system atrophy and olivopontocerebellar atrophy.Ann Neurol 1994; 36 (2): 166–175.

    Article  PubMed  CAS  Google Scholar 

  103. Perani D, Bressi S, Testa D, Grassi F, Cortelli P, Gentrini S, et al. Clinical/metabolic correlations in multiple system atrophy. A fludeoxyglucose F 18 positron emission tomographic study.Arch Neurol 1995; 52 (2): 179–185.

    PubMed  CAS  Google Scholar 

  104. Piccini P, de Yebenez J, Lees AJ, Ceravolo R, Turjanski N, Pramstaller P, et al. Familial progressive supranuclear palsy: detection of subclinical cases using18F-dopa and18fluorodeoxyglucose positron emission tomography.Arch Neurol 2001; 58 (11): 1846–1851.

    Article  PubMed  CAS  Google Scholar 

  105. Blin J, Baron JC, Dubois B, Pillon B, Cambon H, Cambier J, et al. Positron emission tomography study in progressive supranuclear palsy. Brain hypometabolic pattern and clinicometabolic correlations.Arch Neurol 1990; 47 (7): 747–752.

    PubMed  CAS  Google Scholar 

  106. Nagasawa H, Tanji H, Nomura H, Saito H, Itoyama Y, Kimura I, et al. PET study of cerebral glucose metabolism and fluorodopa uptake in patients with corticobasal degeneration.J Neurol Sci 1996; 139 (2): 210–217.

    Article  PubMed  CAS  Google Scholar 

  107. Blin J, Vidailhet MJ, Pillon B, Dubois B, Feve JR, Agid Y. Corticobasal degeneration: decreased and asymmetrical glucose consumption as studied with PET.Movement Disorders 1992; 7 (4): 348–354.

    Article  PubMed  CAS  Google Scholar 

  108. Eidelberg D, Dhawan V, Moeller JR, Sidtis JJ, Ginos JZ, Strother SC, et al. The metabolic landscape of corticobasal ganglionic degeneration: regional asymmetries studied with positron emission tomography.J Neurol Neurosurg Psychiatry 1991; 54 (10): 856–862.

    Article  PubMed  CAS  Google Scholar 

  109. Gilman S, Junck L, Markel DS, Koeppe RA, Kluin KJ. Cerebral glucose hypermetabolism in Friedreich’s ataxia detected with positron emission tomography.Ann Neurol 1990; 28 (6): 750–757.

    Article  PubMed  CAS  Google Scholar 

  110. Rudolf J, Grond M, Hilker R, Ghaemi M, Jacobs A, Heiss W. Relative sparing of the parietal cortex in cerebellar ataxia documented by positron emission tomography.Clinl Neurol Neurosurg 2000; 102 (4): 210–214.

    Article  CAS  Google Scholar 

  111. Leenders KL, Frackowiak RS, Quinn N, Marsden CD. Brain energy metabolism and dopaminergic function in Huntington’s disease measuredin vivo using positron emission tomography.Movement Disorders 1986; 1 (1): 69–77.

    Article  PubMed  CAS  Google Scholar 

  112. Young AB, Penney JB, Starosta-Rubinstein S, Markel DS, Berent S, Giordani B, et al. PET scan investigations of Huntington’s disease: cerebral metabolic correlates of neurological features and functional decline.Ann Neurol 1986; 20 (3): 296–303.

    Article  PubMed  CAS  Google Scholar 

  113. Hayden MR, Martin WR, Stoessl AJ, Clark C, Hollenberg S, Adam MJ, et al. Positron emission tomography in the early diagnosis of Huntington’s disease.Neurology 1986; 36 (7): 888–894.

    PubMed  CAS  Google Scholar 

  114. Mazziotta JC. Huntington’s disease: studies with structural imaging techniques and positron emission tomography.Semin Neurol 1989; 9 (4): 360–369.

    Article  PubMed  CAS  Google Scholar 

  115. Baxter LR Jr, Mazziotta JC, Pahl JJ, Grafton ST, St George-Hyslop P, Haines JL, et al. Psychiatric, genetic, and positron emission tomographic evaluation of persons at risk for Huntington’s disease.Archives of General Psychiatry 1992; 49 (2): 148–154.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Neurologische Universitätsklinik, Max-Planck-Institut für neurologische Forschung, Gleueler Str. 50, 50931, Köln, Germany

    Karl Herholz

Authors
  1. Karl Herholz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Karl Herholz.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Herholz, K. PET studies in dementia. Ann Nucl Med 17, 79–89 (2003). https://doi.org/10.1007/BF02988444

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02988444

Key words

Search

Navigation